Vancouver, British Columbia--(Newsfile Corp. - February 13, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce expansion of its Commercial Partners ProgramTM to support global market growth, through completion of an initial softgel shipment to Australia.Nextleaf Announces Initial Softgel Shipment to AustraliaIn January 2026 Nextleaf served as exporter of ...

Core Insights - High Tide reported record revenue of $164 million for Q4 2025, achieving a revenue run-rate exceeding $650 million and the highest Adjusted EBITDA to date [1][2] - The company remains free cash flow positive for the fiscal year, generating $12 million in fiscal 2025 [4] - High Tide solidified its position as the largest cannabis retailer in Canada with 218 locations and a 12% market share [1][3] Financial Performance - Revenue for Q4 2025 was $164 million, a 19% increase year-over-year and the fastest growth rate in nine quarters [2][3] - Adjusted EBITDA reached a record $12.4 million, up 51% year-over-year, marking the 22nd consecutive positive quarter [2][3] - The company reported a net loss of $46.7 million for Q4 2025, impacted by one-time items, but adjusted net income would have been $1.4 million [2][3] Retail Highlights - Same-store sales increased by 4.1% in fiscal 2025 and rose 5.5% year-over-year in Q4 2025 [2][3] - Canna Cabana's annualized retail sales per square foot were $1,775, consistent year-over-year [2][3] - The company opened 27 new Canna Cabana locations in 2025, achieving the higher end of its target [1][4] Market Expansion - High Tide completed the acquisition of a majority stake in Remexian Pharma GmbH, entering the German medical cannabis market [1][3] - The company is exploring partnerships in the U.K. for distributing medical cannabis products [1][3] - Canna Cabana's membership in Canada surpassed 2.5 million, growing 45% year-over-year [2][4] Operational Developments - The company anticipates opening an additional 20-30 locations in 2026, aiming to surpass 350 locations nationwide [4] - High Tide's white label cannabis product portfolio reached 32 SKUs, with plans for significant growth [4] - The company is evaluating strategic initiatives for its U.S. CBD brands in light of recent federal developments [3][4]

Core Viewpoint - Tilray Medical has rebranded its Italian operations to Tilray Medical Italia, reflecting its commitment to a unified medical cannabis platform in Europe and enhancing its presence in Italy's regulated medical market [1][2][4] Group 1: Strategic Update - The transition to Tilray Medical Italia signifies the company's ongoing efforts to build a scalable medical cannabis platform across Europe [2] - Tilray Medical Italia is expanding its product portfolio with medical cannabis products authorized by the Italian Ministry of Health, in partnership with Molteni Farmaceutici [3][5] Group 2: Market Positioning - Italy is identified as a strategically important market for Tilray Medical, with the rebranding aimed at strengthening local presence and aligning operations under a single global medical brand [4][10] - The company operates within Italy's established medical cannabis framework, supplying products through hospital and pharmacy channels in compliance with national regulations [5][7] Group 3: Product Offerings - Tilray Medical Italia's product portfolio includes various medical cannabis flowers and oils, all EU-GMP certified to meet diverse patient needs [8][9] - The offerings include specific THC and CBD ratios, catering to different therapeutic requirements [9] Group 4: Collaboration and Compliance - The partnership with Molteni Farmaceutici supports physician education, responsible prescribing, and patient access while ensuring high standards for product quality and compliance [6][7] - Tilray Medical Italia aims to responsibly support the evolving demand for medical cannabis in a regulated pharmaceutical environment [7][11]

Cannabis Industry & Tilray Brands - Tilray Brands anticipates potential rescheduling of marijuana to schedule three drug by President Trump, which would reduce federal restrictions [1][3] - Rescheduling would allow Tilray to enter the US market, leveraging research and clinical studies from Canada and Europe, focusing on medical cannabis [5] - Tilray aims to collaborate with the FDA, hospitals, and doctor groups to provide cannabis for medical purposes, such as cancer, epilepsy, stress, and sleep [5][6] - Tilray has over 6 million square feet of cannabis grow space in Canada and Europe, planning to bring strains and genetics to the US [6] - Tilray estimates a potential US medical cannabis market of $10 billion, with a target of 3% to 10% market share, translating to a $300 million to $1 billion business [8] - Tilray has a $50 million business selling cannabis drinks in Canada, and sees potential opportunities in the US with regulated hemp THC products [14] Market Trends & Economic Data - S&P 500 equal weighted index has been outperforming recently, up about 3% in the last month [22] - Healthcare sector (XLV) is the best performing sector this quarter, up 12%, while financials are up about 2% [24] - Crude oil settled at the lowest point in four years at $5665 per barrel, down about 20% this year, while energy sector is up about 5% year-to-date [29][30] - Bitcoin is down 22% year-to-date, with shorts in control and a washout point at $75,000 [33] Women in the Workplace - A McKenzie report indicates a gap between men and women in seeking promotions in corporate environments [36] - A study indicates 86% of senior women leaders are more ambitious than five years ago, seeking flexibility, autonomy, and control [37] - 89% of women queried said they've made a massive change in the last few years, with 71% of those women making that decision by choice [40]

Core Insights - JAZZ Pharmaceuticals is an unconventional player in the cannabis sector, having entered the market through the acquisition of GW Pharmaceuticals in 2021, which added the FDA-approved CBD drug Epidiolex to its portfolio [1][2] - The company is well-positioned for long-term gains as the medical cannabis market evolves and regulatory clarity improves [2] Epidiolex's Contribution - Epidiolex has become a significant revenue contributor, accounting for a quarter of JAZZ's total revenues [3] - In the first nine months of 2025, Epidiolex generated over $772 million in product sales, reflecting an 11% year-over-year increase [4] - The global medical cannabis market is projected to exceed $130 billion by 2032, providing JAZZ with a unique opportunity due to its established FDA-approved product [5] Diverse Product Lineup - JAZZ has a diverse product lineup beyond cannabis, including drugs for neuroscience and oncology [6] - Xywav, a low-sodium formulation for narcolepsy, is a key product that offers advantages over its predecessor, Xyrem [7] - The oncology segment includes six drugs that now contribute over 26% to JAZZ's topline, driven by new launches and increased market share [8] Pipeline Developments - JAZZ is focused on expanding the labels of its oncology drugs, with promising results for Ziihera in treating HER2+ gastroesophageal adenocarcinoma [9] - Despite setbacks in its pipeline, including the discontinuation of suvecaltamide and underwhelming results for JPZ150, the company continues to explore options for its drug development [12][13] Stock Performance and Outlook - JAZZ's stock has surged 46% year-to-date, outperforming the industry average of 20% [14] - EPS estimates for 2025 and 2026 have trended upward, indicating a stronger outlook compared to other cannabis-focused companies [15] - The company offers a diversified revenue base, making it suitable for investors seeking balanced biotech exposure rather than a direct cannabis investment [16][17]

Core Insights - IM Cannabis Corp. is set to report its operational and financial results for Q3 2025 on November 13, 2025, before market opening [1] Company Overview - IM Cannabis Corp. is an international cannabis company focused on providing premium cannabis products to medical patients in Israel and Germany, which are among the largest medical cannabis markets [2] - The company aims for sustainable and profitable growth in its key markets, leveraging a data-driven approach and a globally sourced product supply chain [2] - IM Cannabis is committed to responsible growth and compliance with strict regulatory environments to enhance its commercial and brand power [2] Operational Ecosystem - The IMC ecosystem operates in Israel through subsidiaries that import and distribute cannabis to medical patients, utilizing proprietary data and patient insights [3] - The company manages medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel to ensure safe delivery and quality control of its products [3] - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [3]

Core Viewpoint - Cannabis stocks experienced significant gains following President Donald Trump's promotion of a video advocating for the inclusion of cannabidiol (CBD) under Medicare coverage [1][6]. Group 1: Stock Performance - Tilray Brands surged nearly 20% and was up 36% after market open [1]. - Canopy Growth jumped about 20%, while Cronos Group rose 13% [1]. - Aurora Cannabis climbed 13.3%, and Trulieve Cannabis spiked almost 20% [1]. - Green Thumb Industries, Curaleaf Holdings, and Innovative Industrial Properties also saw considerable share price increases [3]. Group 2: Video Promotion and Content - The video produced by The Commonwealth Project features Trump and a narrator advocating for wider access to CBD for seniors [6][9]. - The narrator claims that hemp-derived CBD can significantly improve the quality of life for older adults [7][10]. - The video suggests that CBD can help restore the endocannabinoid system and assist with pain, sleep, and stress [10]. Group 3: Regulatory Context - Trump previously indicated he was considering reclassifying marijuana as a less dangerous substance, although no action has been taken yet [8]. - The timing of the video promotion coincides with Congress deliberating on tightening hemp regulations, with some Republicans advocating for stricter limits on CBD products containing trace amounts of THC [8].

Financial Performance - High Tide Inc. reported record-high revenues, gross profit, and free cash flow for Q2-2025, marking it as the best quarter in the company's history [1] Market Expansion - High Tide has officially entered the German medical cannabis market, indicating a strategic expansion into new territories [1]

Core Insights - Aurora Cannabis Inc. is recognized as one of the 12 best marijuana stocks to buy according to analysts [1] - The company, in collaboration with Copeia, has launched an English-language version of the Physician Experience Platform (PEP), which includes over 130 anonymized case studies on medicinal cannabis treatments [1][2] - PEP aims to provide healthcare professionals with access to peer-reviewed clinical insights and is initially available in several countries including Canada, the UK, and Australia [1][2] Company Developments - The PEP platform builds on a successful German launch in 2024 and is secured by a DocCheck login for verified physicians [2] - Aurora Cannabis operates in the global medicinal and consumer cannabis markets under various brands such as MedReleaf, CanniMed, Drift, and San Rafael '71 [2] - The company intends to create an international medical cannabis case study database for physicians to upload cases in the future [2]

Core Insights - Tilray Medical is expanding its presence in Germany's medical cannabis market by introducing three new EU-GMP certified cannabis strains, enhancing patient and pharmacy access [1][2][3] Product Offerings - The new strains include Good Supply Cannabisblüten THC 22 IIM, THC 25 MMK, and THC 18 LLD, available in 15 g and 500 g sizes to cater to diverse needs [1][2] - Good Supply Cannabisblüten THC 22 IIM will be available from early September, THC 25 MMK from September 19, and THC 18 LLD by late September or early October [2] Market Positioning - Tilray Medical aims to be a trusted partner in medical cannabis, leveraging its robust international platform and distribution network to ensure consistent quality and reliable supply [2][3] - The company has established itself as a leading supplier of medical cannabis, with a portfolio that includes several recognized brands tailored for the German market [3][4] Company Background - Tilray Medical has evolved from being one of the first licensed producers of medical cannabis in Canada to building GMP-certified production facilities in Portugal and Germany [4] - The company is committed to providing safe and reliable access to a global portfolio of medical cannabis brands, including Good Supply, Broken Coast, Redecan, and Navcora [4] Strategic Goals - The introduction of new strains is part of Tilray's broader strategy to enhance healthcare standards and patient care globally [2] - The company emphasizes its dedication to transforming healthcare through informed health decisions and individualized patient care [1][2]